initi coverag market outperform ctic get new leas life
initi coverag cti biopharma market outperform rate
price target base discount cash flow compar
compani analys cti clinical-stag biopharmaceut compani focus
develop pacritinib treatment myelofibrosi pacritinib
long develop histori myelofibrosi includ two phase studi
show strong sign efficaci patient popul high unmet need
compani also small meaning revenu stream partner
commerci product pixuvri trisenox help avoid
delay dilut financ also possibl pixuvri commerci
 on-going studi show surviv benefit
lead product candid pacritinib high likelihood achiev
regulatori approv eu opinion pacritinib shown
clinic benefit patient popul address jakafi ruxolitinib
mo pt bayko approv drug myelofibrosi model
contempl approv two patient popul eu japan
peak sale estim nearli pacritinib clinic hold
due suspect death imbal appar full dataset
analyz overhang cti share last throughout
compani demonstr pacritinib straightforward path market
see upsid share valu remind investor fedratinib place
clinic hold fda four year prior resurrect team impact
bioscienc lead impact acquisit celgen celg mp
believ manag team well equip bring pacritinib
market realiz full commerci potenti adam craig ph
becam ceo februari year experi hematology/
oncolog drug develop dr craig chanc consult compani
sever month review clinic data interact regulatori author
prior make decis join full-tim basi view addit dr
craig appoint three new independ director turn
point compani long sometim troubl histori significantli boost
chanc success commerci pacritinib
compani well fund achiev near-term goal signific
catalyst expect recent equiti offer brought
compani plan use complet two on-going clinic studi explor possibl
addit indic pacritinib accord estim compani
current cash posit provid runway notabl
number key mileston includ complet studi potenti
market approv eu
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
cti biopharma undergon mani incarn sinc found seattl washington
singer jim bianco mani year ctic previous known cell
poster child mani issu investor critic biotech compani overspend poor
decis make clinic trial strategi regulatori relationship along highli dilut
persona ctic becam irrevoc tie person jim bianco md career
import medicin train mount sinai medic center new york achiev statu
director marrow transplant seattl va medic center seattl brilliant
physician sharp eye product in-licens opportun cti experi sever
misstep clinic trial number compound along way dr bianco alien
mani investor high-spend person wore expens cloth corpor
behavior includ use privat aircraft
also merger milan italy-list novuspharma brought anthracyclin
drug pixantron pixuvri well list milan exchang list sit well
 investor due differ view valuat cti also seemingli addict continu
dilut financ via prefer share offer often includ warrant turn made
difficult investor determin fulli dilut share count given day
thu mani investor opt simpli ignor ctic invest name dr bianco also employ
brother loui bianco cfo
dr bianco credit pacritinib jak inhibitor key driver compani valuat
proposit today identifi stewardship howev clinic hold place
drug develop investor left name manifest frustrat
replac jim bianco loui bianco remaind manag team
new team place led dr adam craig clinic hold lift pacritinib
stake compani stori invest fund bvf partner balanc sheet bolster
recent financ believ cti readi move new phase corpor life cycl
one think mark success
respons day letter analysi phase ii myelofibrosi enrol opinion data phase ii myelofibrosi data phase rituximab combo aggress b-cell nhl cti biopharma corp ctic
deriv price target base synthesi discount cash flow dcf compar
dcf valuat project world-wide sale pacritinib myelofibrosi subtract cog
project oper expens tax net cash flow compani discount back present
day use integr risk-adjust blend discount rate
termin valu compani calcul appli long-term growth rate
discount present day present valu cash flow togeth termin valu
ad arriv residu valu estim cash long-term debt ad
subtract respect therebi arriv equiti valuat divid
estim current outstand share count deriv per share valuat dcf
assumpt detail figur
synthesi valuat approachesapproachvaluationweightdcf cti biopharma corp ctic
also arriv valuat take mean market cap valuat peer group clinic
stage small-molecul oncolog compani deriv compar valuat cti figur
cti biopharmadiscount revenu total myelofibrosisu sales- eu sales- japan royalties- total revenu product oper incom oper margin tax oper valu cash long-term dilut share discount rate growth capdebtevgeron bioscienc biopharma biotech compani cti biopharma corp ctic
cti biopharma corp biopharmaceut compani engag acquisit develop
commerci novel target therapi blood-rel cancer unit state
intern primarili focus develop pacritinib investig oral kinas inhibitor
specif phase clinic trial treatment
myelofibrosi addit develop tosedostat oral once-daili aminopeptidas inhibitor
phase ii clinic trial treatment acut myeloid leukemia compani also focus
commerci pixuvri aza-anthracenedion treatment adult patient multipli
relaps refractori aggress b-cell non-hodgkin lymphoma european union compani
licens collabor agreement le laboratoir servier institut de recherch
international servier agreement univers vermont ltd gynecolog oncolog
group pg-txl compani licens agreement vernali limit
compani formerli known inc chang name cti biopharma corp
may cti biopharma corp found headquart seattl washington
clinic drug develop inher riski busi clinic trial alway carri risk failur
ctic asset may fail demonstr signific enough level efficaci current futur
regulatori commerci abil ctic market drug pipelin depend upon
drug obtain approv fda foreign regulatori agenc failur achiev
approv delay timelin approv could neg impact compani share price
competit cancer therapeut develop intens competit industri domin
biotechnolog pharmaceut compani expertis resourc may greater
ctic adequ well-fund cash cash equival short-term
invest howev compani may requir addit equiti financ form secondari
offer complet develop drug candid
revenu model cti biopharma integr forecast sale pacritinib eu
japan treatment myelofibrosi detail summari pipelin revenu sale
project market model estim provid figur
model also includ royalti revenu pixuvri licens servier countri
outsid unit state pixuvri revenu small part overal project revenu cti
averag per year next decad revenu come
model includ pacritinib two myelofibrosi popul patient platelet count
patient prior ruxolitinib exposur
forecast first approv pacritinib treatment patient low platelet count
european union eu market author applic current
review expect approv requir least one addit phase studi lead
approv patient popul well eu patient prior ruxolitinib exposur
japan model forecast commerci launch patient popul
territori estim approxim patient diagnos myelofibrosi
platelet count prior ruxolitinib exposur progress patient approxim
calcul fraction patient elig pacritinib base preval estim
patient eu japan conserv estim length
treatment nine month territori
uspacritinib myelofibrosi patientsmyelofibrosi preval us platelet count low platelet count low platelet platelet count patient ruxolitinib refractori inelig refractori refractori patient patient therapi patient month therapi per price sale pacritinib- cti biopharma corp ctic
eupacritinib myelofibrosi patientsmyelofibrosi preval platelet count low platelet count low platelet platelet count patient ruxolitinib refractori inelig refractori refractori patient patient therapi patient month therapi per price sale pacritinib- japanpacritinib myelofibrosi patientsmyelofibrosi preval platelet count low platelet count low platelet platelet count patient ruxolitinib refractori inelig refractori refractori patient patient therapi patient month therapi per price sale pacritinib- cti biopharma corp ctic
myeloprolif neoplasm mpn chronic disord character overproduct
hematopoiet stem cell group base presenc philadelphia chromosom
mutat chronic myelogen leukemia cml philadelphia-posit diseas
philadelphia-neg neoplasm divid polycythemia vera pv essenti thrombocythemia
et myelofibrosi mf mf may develop primari diseas secondari either pv et
mpn involv genet mutat caus abnorm prolifer blood stem cell
typic group type cell affect et mark overproduct platelet
pv mf involv hyperprolifer red white blood cell respect mf caus
progress bone marrow fibrosi transform acut leukemia transform
common patient low platelet count time diagnosi huang et al cancer
strongli neg impact prognosi reduc median surviv time five year
five month et al blood
bone marrow fibrosi characterist mf often result blood cell product shift
spleen result splenomegali enlarg spleen spleen volum reduct often use clinic
endpoint mf studi target therapi marker improv underli caus mf
clinic manifest mf character fatigu chest pain due enlarg spleen
fever bone pain mf also
hematopoiesi anemia thrombocytopenia et al lancet mf often develop slowli
mani patient experi symptom earli stage mf stratifi risk-level
lower risk patient often left untreat symptom worsen
mf like mpn link aberr jak-stat janu associ kinase-sign transduc
activ transcript signal mutat calreticulin calr myeloprolif
leukemia viru mpl gene present case tefferi et al leukemia
mutat far common occur mf patient mascarenha et al
blood payzin et al clinic lymphoma myeloma leukemia grinfeld et al
haematologica jak-stat pathway critic intracellular signal cascad play
role transduct extracellular signal nucleu control gene express varieti
cytokin act jak-stat pathway drive divers process hematopoiesi
immune-regul fertil lactat growth embryogenesi
ruxolitinib jak inhibitor current approv therapi mf sinc first hit
market ruxolitinib grown penetr mf market like jak inhibitor
current previous develop target jak-stat pathway caus myelosuppress
thrombocytopenia indic patient platelet count
patient inelig ruxolitinib common therapi target symptom anemia
blood transfus immunomodulatori drug enlarg spleen chemotherapi radiat
splenectomi believ cur therapi mf stem cell transplant
seriou limit procedur major patient frail undergo transplant
one-year surviv rate ballen blood cancer
pacritinib small-molecul kinas inhibitor design scientist target atp bind
pocket aid comput chemistri hart et al leukemia molecul
previous call pyrimidine-bas macrocycl exhibit strong prefer
kinas jak famili pacritinib also potent inhibitor target
relev acut myelogen leukemia aml well tyrosin kinas figur
figur kinas inhibit profil pacritinib concentr
unlik jak inhibitor develop pacritinib nm affin figur
singer et al pharmacol less myelosuppress ruxolitinib bjorn et al leuk
figur rel kinas profil select jak inhibitor
cti acquir pacritinib april asset purchas agreement includ
up-front payment prefer stock convert common stock cti time
pacritinib evalu phase phase ii clinic trial varieti hematolog
malign includ mf hodgkin lymphoma aml cml
phase ii studi pacritinib mf assess fraction patient achiev svr well
safeti toler week patient svr mf symptom
improv patient except fatigu komrokji et al blood diarrhea
nausea common side effect patient discontinu due
advers event includ sever event patient
base result bio phase ii mf trial cti initi two phase clinic trial mf
patient enrol patient platelet count enrol patient
platelet count pacritinib less myelosuppress ruxolitinib could
ideal therapi patient at-risk prescrib ruxolitinib trial
enrol mf patient across europ randomli assign pacritinib mg
qd best avail therapi bat enrol patient random
receiv pacritinib qd pacritinib bid bat
bat includ ruxolitinib trial option bat
outcom phase persist trial
full analysi trial show patient pacritinib achiev svr
compar bat bat primarili hydroxyurea intervent
unapprov agent typic use mf mean absolut reduct svr
time point chang significantli week figur
figur persist spleen volum reduct svr
total symptom score tss also found reduc patient take pacritinib
reduct achiev patient vs bat patient pacritinib improv rapidli
effect grew stronger week figur
figur improv total symptom score tss
abil pacritinib induc svr improv symptom clearli signific trial
advers event patient death dropout gener seriou concern compound
patient receiv pacritinib discontinu due advers event withdrew result
patient investig decis patient die patient discontinu pacritinib due
progress diseas patient still take pacritinib time place clinic
hold howev although differ overal surviv signific trend final analysi
favor pacritinib hr ci
trial enrol patient low platelet count notabl pivot
phase trial led ruxolitinib approv mf exclud patient platelet count
unlik trial enrol patient previous treat
ruxolitinib inhibitor studi design similar svr
tss co-primari endpoint three random cohort mg qd mg bid
bat roughli half patient platelet count receiv prior ruxolitinib
fraction patient bat group receiv ruxolitinib trail also
patient receiv hydroxyurea watch wait intervent
patient receiv prior ruxolitinib pacritinib qd produc respons rate bid
dose yield respons rate mascarenha et al blood
fraction patient achiev svr larg consist
figur show comparison two trial broken platelet count time
enrol bat group trial includ patient low platelet count treat
ruxolitinib one achiev svr
figur spleen volum reduct patient platelet count
et al lancet hematolog mascarenha et al blood
trial patient discontinu treatment pacritinib arm higher rate
patient bat due advers event pacritinib qd pacritinib bid bat figur
patient slightli less like discontinu due diseas progress pacritinib pacritinib
qd pacritinib bid bat discontinu reason occur similar frequenc
three cohort except patient cross bat pacritinib
figur dose interrupt reduct discontinu persist trial
et al lancet hematolog mascarenha et al blood
importantli pacritinib exacerb thrombocytopenia patient platelet count
overal figur popul ruxolitinib indic approv therapi
figur chang platelet count trial
although phase persist trial show promis clinic activ patient low
normal platelet count meaning safeti concern emerg februari fda place full
clinic hold pacritinib end pacritinib treatment patient take part phase persist
trial neither trial complet patient evalu fulli enrol time
hold clinic hold base interim analys trial appear show death
imbal treatment arm trial death thought attribut pacritinib
caus intracrani hemorrhag cardiac failur cardiac arrest cti analyz data avail
time pacritinib place hold includ follow month beyond data use
fda interim evalu led hold complet dataset trial show
death imbal due pacritinib fda lift hold januari cti also agre
initi trial dose-find phase ii studi evalu safeti efficaci patient
previous treat ruxolitinib
set asid purport death imbal persist trial mark seriou advers
event sae limit toler pacritinib advers event ae data persist trial
reproduc figur common treatment-rel trial diarrhea
nausea affect patient compar patient bat
similar pacritinib qd bid group sae common group
note rate sae bat patient half ruxolitinib also
full analysi data avail time clinic hold show differ
overal surviv summari death occur trial shown figur
figur summari death trial
trial dose-find phase ii studi request fda follow clinic hold
pacritinib evalu safeti efficaci patient previous treat ruxolitinib began
enrol patient juli enrol goal three dose test mg
qd mg bid mg bid goal trial find minimum effect dose
pacritinib second-lin patient interim svr data trial expect
cti use interim result determin dose discontinu
base result persist trial predict optim combin safeti efficaci
achiev mg bid dose howev import mg bid dose
overlook efficaci lower dose would potenti allow label includ dose
reduct outcom studi critic pacritinib chanc obtain approv
view pacritinib must prove accept safe rel fragil mf popul particularli
low platelet count meet aim mitig potenti drug-rel death
seriou advers event cti employ stringent cardiac inclus criteria studi
patient bleed episod past six month exclud expect cti
meet fda follow conclus phase ii studi plan follow-up phase
studi nda submiss
eu submit european medicin agenc ema june pacritinib
patient low platelet count compani receiv day list question loq
anticip respond issu may concern rais loq involv safeti
efficaci size dataset pharmacokinet pk analys dose regimen
trial respons loq includ addit pk data on-going trial
patent cover pacritinib composit matter set expir compound
salt eu compound salt salt formul use
clinic trial improv physic stabil product expect see potenti
gener competit prior expir salt patent either market
pixuvri pixantron anthraquinone-bas inhibitor topoisomeras ii long develop
histori non-hodgkin lymphoma nhl mf pixuvri structur relat anthracyclin
anthracenedion broad class widely-us chemotherapi drug includ doxorubicin
appear associ level cardiotox effect pixuvri structur
design bind iron perpetu oxygen radic product form long-liv
hydroxyl metabolit put mechan anthracycline-induc acut
chronic cardiotox cti first acquir right pixuvri merg novuspharma
composit matter licens univers vermont patent relat
pixuvri expir european patent cover pixuvri composit method
use began expir last set expir
european commiss grant condit market author european union eu
pixuvri monotherapi treatment adult patient multipli relaps refractori
aggress nhl may pixuvri first treatment approv eu patient
multipli relaps refractori aggress b-cell nhl approv base result pivot
phase clinic trial known extend enrol patient show
pixuvri induc complet respons unconfirm complet respons patient
compar placebo common sae observ neutropenia leukopenia
thrombocytopenia asthenia pyrexia cough grade cardiac seen patient
take pixuvri vs placebo number death due equal two arm
connect condit market author cti requir conduct post-approv
trial intend confirm pixuvri clinic benefit phase clinic trial compar
pixantron rituximab gemcitabin rituximab set aggress b-cell nhl began
enrol patient top-lin result expect origin primari endpoint
trial overal surviv os chang progression-fre surviv decemb
approv european medicin agenc allow compani lower enrol
target
result suffici obtain condit market approv eu nda file
fda reject due concern around safeti efficaci receiv
complet respons letter fda reject approv pixuvri cti request
acceler approv fda divis oncolog product accept
nda assign pdufa date withdrawn cti februari allow
addit time prepar necessari inform cti current plan pursu approv
pixuvri decis could reevalu base result trial
april cti enter exclus licens agreement laboratoir servier servier
develop commerci pixuvri world-wide except nine
countri cti receiv up-front payment possibl futur mileston
payment cti servier amend agreement april grant servier exclus world-wide
develop commerci right pixuvri outsid cti receiv up-front
payment potenti receiv addit regulatori mileston
sales-bas mileston well tier royalti net sale agreement expir base
royalti term determin country-by-countri basi allow servier continu sell pixuvri
without make royalti payment cti
trisenox gener arsenic-contain compound use induct therapi relapsed/refractori
acut promyelocyt leukemia compound sold teva pharmaceut teva nc
sinc cti receiv mileston payment includ februari
elig specif sale develop mileston reach
ruxolitinib highli select inhibitor market drug indic treatment
mf approv back two phase studi evalu svr
patient ruxolitinib placebo two trial patient
ruxolitinib achiev svr week compar one patient placebo
conduct five-year surviv analysi patient pool two phase studi
note patient achiev svr point trial long-term follow
show median overal surviv os significantli improv year hr
ci effect even pronounc correct crossov
decemb ruxolitinib label indic prescrib patient platelet
count low reduc dose mg bid compar mg bid patient
sale ruxolitinib climb steadili first full year sale
billion expect revenu grow billion ruxolitinib clear leader
mf expect remain commonli prescrib front-lin treatment forese
futur see signific market avail pacritinib patient take ruxolitinib due
low platelet count patient stop respond drug
advanc pipelin asset mf fedratinib celg mp advanc phase
clinic trial impact biomedicin compani acquir celgen januari
billion acquisit price subject achiev regulatori commerci
mileston fedratinib like pacritinib ruxolitinib jak inhibitor slightli differ select
toxic profil prior acquir impact sanofi advanc fedratinib phase
jakarta trial enrol patient found signific reduct svr patient take
fedratinib mg qd drug place clinic hold fda due seriou
safeti concern sanofi abandon develop
impact acquir compound exchang equiti persuad fda lift clinic hold
show concern side effect due thiamin deplet could manag
view fedratinib may compet pacritinib patient stop respond ruxolitinib
less like use patient low platelet count caus
grade thrombocytopenia patient rate similar ruxolitinib studi fedratinib
post impress svr rate patient previous treat ruxolitinib
earlier-stag mf pipelin includ addit jak inhibitor well compound target
varieti receptor signal kinas figur figur list asset current phase ii
figur molecular target myelofibrosi
adam craig ph chief execut offic dr craig appoint serv director
presid chief execut offic march dr craig work independ
consult provid strateg oper advic support cti biopharma
hematology/oncolog biotechnolog compani sinc prior consult dr craig chief
medic offic execut vice presid develop
dr craig senior vice presid chemgenex
pharmaceut ltd publicli trade biotechnolog compani acquir cephalon/teva
pharmaceut dr craig member royal colleg physician uk undertook
post-gradu train pediatr pediatr oncolog dr craig earn bachelor
medic degre chare cross westminst medic school univers london hold
ph molecular oncolog leed univers uk open busi
school unit kingdom dr craig recent serv product develop review
cancer prevent research institut texa
 singer evp chief scienc offic interim chief medic offic global head
translat medicin singer founder cti biopharma current serv
compani execut vice presid chief scientif offic interim chief medic offic
global head translat medicin dr singer one compani director sinc
incept septemb june dr singer compani chief medic
offic juli januari dr singer execut vice presid research program
chairman april juli serv execut vice presid research
develop also serv board director inc
prior join cti dr singer professor medicin univers washington full
member fred hutchinson cancer research center chief
medic oncolog veteran administr medic center seattl dr singer receiv
state univers new york downstat medic colleg
bruce seeley evp chief oper offic bruce seeley join cti biopharma juli
execut vice presid chief commerci administr offic secretari septemb
promot chief oper offic mr seeley lead cti biopharma commerci
organ world-wide includ sale market commerci oper medic affair suppli
mr seeley year global commerci experi proven track record
success launch product variou market regulatori environ recent mr
seeley senior vice presid gener manag diagnost nanostr technolog
inc overse launch diagnost product prosigna early-stag breast cancer
previous execut vice presid commerci seattl genet built led
commerci organ includ market sale manag market success
launch compani first product adcetri target therapi lymphoma also
previous held key leadership posit market genentech member roch
group led launch herceptin adjuv breast cancer earlier career
held variou commerci role aventi pharmaceut inc part sanofi bristol-my
squibb co mr seeley receiv sociolog univers california lo angel
david kirsk evp chief offic mr kirsk appoint princip
account offic august septemb promot chief offic
mr kirsk lead cti biopharma financ account investor relat team prior
appoint mr kirsk independ chief financi offic cfo consult sinc januari
consult provid financi manag servic public emerg growth
privat compani primarili biotechnolog industri well technolog manufactur
mr kirsk financi manag experi includ overse financ account oper
capit debt equiti prior time consult mr kirsk serv vice
presid cfo helix biomedix manag financi administr activ
previous treasur corpor control network redhook breweri
manag corpor intern entiti well part manag
team led execut compani success initi public offer earlier career
held controllership posit cray comput mr kirsk hold busi administr
univers puget sound
laurent fischer cti director sinc juli appoint chairman
septemb dr fischer appoint senior vice presid head liver area
allergan follow acquisit tobira therapeut dr fischer serv senior advisor
frazier healthcar partner life scienc team sinc march previous chairman
ceo jennerex inc compani first-in-class oncolyt immunotherapi liver cancer
acquir million sillajen co-found presid ceo ocera therapeut
held senior posit dupont-merck hoffmann-la roch liver
diseas virolog oncolog dr fischer receiv undergradu degre univers
geneva medic degre geneva medic school switzerland
richard director sinc septemb mr present manag
translat acceler llc mr also director parexel intern corpor
prxl publicli trade compani director follow privat compani
inc cerrx inc previous director imarx therapeut inc prior acquisit
cti juli serv chairman board system medicin inc start two
biopharmaceut compani triton bioscienc inc ilex oncolog inc serv chief
execut offic triton bioscienc chief execut offic ilex
oncolog addit mr serv execut posit not-for-profit
organ includ cancer therapi research center san antonio technolog
acceler initi translat genom research institut mr receiv
chemic engin virginia polytechn institut
michael metzger join cti biopharma board januari mr metzger current presid
chief oper offic syndax pharmaceut inc publicli trade immuno-oncolog
biopharmaceut compani mr metzger serv presid chief execut offic regado
bioscienc inc former publicli trade biotechnolog compani
oversaw compani success merger tobira therapeut inc act
advisor tobira subsequ sale allergan previous mr metzger serv
execut vice presid chief oper offic mersana therapeut privat held
biotechnolog compani develop novel immunoconjug therapi cancer
senior busi develop posit includ lead merger acquisit forest
laboratori inc mr metzger serv vice presid corpor develop
onconova inc manag director partner
inc ventur capit firm mr metzger hold georg washington
univers financ new york univers stern school busi
david parkinson cti director sinc june dr parkinson serv
presid chief execut offic inc sinc dr parkinson serv
ventur partner new enterpris associ nea inc sinc move
role ventur advisor nea dr parkinson serv presid ceo
nodal biotechnolog compani focus biolog character signal pathway
patient malign enabl effect therapeut develop clinic decision-
make dr parkinson previous led oncolog clinic develop activ novarti
biogen idec work nation cancer institut
serv chief investig drug branch act associ
director cancer therapi evalu program ctep dr parkinson past chairman
food drug administr fda biolog advisori committe also serv fda
scienc board recipi fda codi medal held academ posit
tuft univers texa md anderson cancer center author peer-
matthew perri director sinc januari mr perri presid bvf partner
 portfolio manag underli fund manag firm bvf partner privat
invest partnership focus small-cap valu orient invest opportun
year mr perri join bvf partner decemb success lead
investor dozen transact posit influenc corpor direct numer
biotechnolog compani cours career mr perri also co-found director
nordic biotech advisor ap ventur capit firm base copenhagen denmark hold
degre biolog depart colleg mari
frederick tell ph cti director sinc decemb prior retir
dr tell corpor offic recent vice presid corpor polici
strateg manag sinc join respons strateg
plan polici develop throughout major career current serv chairman
oragen inc board director eisai aequu biopharma inc majority-
own subsidiari aequu dr tell receiv hamilton colleg master
industri labor relat ph econom public polici cornel univers
reed tuckson facp join cti board septemb dr tuckson serv
manag director tuckson health connect privat consult compani decemb
march dr tuckson serv execut vice presid chief medic affair
novemb decemb serv senior vice presid
clinic affair unitedhealth group dr tuckson also serv senior vice presid
profession standard american medic associ presid charl drew
univers medicin scienc lo angel senior vice presid program march
dime birth defect foundat commission public health district columbia
current serv board director allianc health reform american telemedicin
associ project sunshin arnold gold foundat advisori committe
nation institut altern integr medicin dr tuckson receiv
zoolog howard univers georgetown univers school medicin
complet hospit univers pennsylvania gener intern medicin resid
